Actively Recruiting

Phase 2
Age: 18Years - 55Years
All Genders
NCT04637620

NMDA Modulation in Major Depressive Disorder

Led by China Medical University Hospital · Updated on 2025-02-19

90

Participants Needed

1

Research Sites

495 weeks

Total Duration

On this page

Sponsors

C

China Medical University Hospital

Lead Sponsor

M

Ministry of Science and Technology, Taiwan

Collaborating Sponsor

AI-Summary

What this Trial Is About

Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.

CONDITIONS

Official Title

NMDA Modulation in Major Depressive Disorder

Who Can Participate

Age: 18Years - 55Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a DSM-5 diagnosis of major depressive disorder (MDD)
  • Have a 17-item Hamilton Rating Scale for Depression total score of 18 or higher
  • Be free of antidepressant drugs for at least 2 weeks before the study
  • Agree to participate in the study and provide informed consent
  • Be between 18 and 55 years old
Not Eligible

You will not qualify if you...

  • Current substance abuse or history of substance dependence in the past 6 months
  • History of epilepsy, head trauma, stroke, or other serious medical or neurological illness that may interfere with the study
  • Diagnosis of bipolar depression, schizophrenia, or other psychotic disorders
  • Moderate to severe suicidal risk
  • Severe cognitive impairment
  • Starting or stopping formal psychotherapy within 6 weeks prior to enrollment
  • History of severe adverse reactions to SSRIs
  • History of treatment resistance, defined as failure to respond to two or more different classes of antidepressants
  • History of receiving electroconvulsive therapy
  • Inability to follow the study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan

Actively Recruiting

Loading map...

Research Team

H

Hsien-Yuan Lane, M.D., Ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here